Skip to main content

Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo

Jan 04, 2016 12:00 am

Tofacitinib has been approved for use in rheumatoid arthritis. While attempts to prove its efficacy in psoriasis have not been successful (http://buff.ly/1R6aRF4), early uncontrolled reports have suggested its potential utility in other skin disorders.

Vitiligo is an autoimmune depigmenting disorder for which there is no effective therapy. Recent reports in JAMA dermatology have shown the efficacy of tofacitinib in patients with vitiligo  (Citation source http://buff.ly/1Jo3dDe). 

Alopecia universalis can be a devastatingly recalcitrant condition. Early uncontrolled reports of major improvement with ruxolitinib or tofacitinib has led to a randomized trial of tofacitinib in alopecial universalis (currently in progress). A recent report has also shown that tofacitinib may improve the nail dystrophy that accompanies this condition. (Citation source http://buff.ly/1kDXZHZ)

A similar report from researchers at Yale has shown the efficacy of uncontrolled tofacitinib in patients with severe eczema. (Citation source http://buff.ly/1Jo6Jh9)

 

Disclosures
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×